ASPC

#4496
A SPAC III Acquisition Corp. - Class A Ordinary Shares
10.8 7 USD
-0.01%
Market Price
Settore: Finanziario
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
10.87
10.87
Intervallo Annuale
10.51
15.55
Variazione giornaliera
-1.18%
Variazione Mensile
+2.94%
Variazione di 6 mesi
-6.05%
Variazione Annuale
-10.90%
Chiusura Precedente
11.0 0
Open
10.8 7
Minimo
10.8 7
Massimo
10.8 7
Volume
1
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Quarterly report, Q2 FY2026
ASPAC III Acquisition Corp. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
ASPAC III Acquisition Corp. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
ASPAC III Acquisition Corp. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
ASPAC III Acquisition Corp. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ASPAC III Acquisition Corp. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
ASPAC III Acquisition Corp. annual report, FY2025
10-K
Current report, Q4 FY2025
ASPAC III Acquisition Corp. current report, Q4 FY2025
8-K
Quarterly report, Q3 FY2025
ASPAC III Acquisition Corp. quarterly report, Q3 FY2025
10-Q
Quarterly report, Q2 FY2025
ASPAC III Acquisition Corp. quarterly report, Q2 FY2025
10-Q
Current report, Q2 FY2025
ASPAC III Acquisition Corp. current report, Q2 FY2025
8-K

ASPAC III Acquisition Corp. current report, Q1 FY2025

Full document

Business Context and Reporting Period

Company: ASPAC III Acquisition Corp. (ASPCU/ASPC/ASPCR)
Filing Date: January 24, 2025
Event: Entry into a Material Definitive Agreement (Item 1.01) with Bioserica International Limited ("Bioserica").
Target Profile: Bioserica is engaged in the research, development, manufacturing, marketing, and sales of bio-based antimicrobial materials.

Key Financial Metrics and Transaction Terms

Transaction Structure: The deal involves a Reincorporation Merger followed by an Acquisition Merger. ASPAC III will merge into a new BVI entity ("Purchaser"), which will then merge with Bioserica via a subsidiary ("Merger Sub").
Consideration: The aggregate consideration for Bioserica shareholders is $200,000,000, paid entirely in stock.
Valuation: Newly issued ordinary shares of the Purchaser are valued at $10.00 per share.
Share Conversion: Existing ASPAC III units will separate into shares and rights; rights will convert to 1/10th of a share. All existing Purchaser shares will be cancelled and retired.
Financial Data: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either party. Investors must refer to future proxy statements for audited financials.

Material Changes and Conditions

Material Change: The execution of the Agreement represents a potential initial business combination, subject to the execution of definitive agreements.
Key Conditions to Closing:

  • SEC declaration of effectiveness for the registration statement (Form F-4 or S-4).
  • Shareholder approval from both ASPAC III and Bioserica.
  • Completion of the China Securities Regulatory Commission (CSRC) filing by Bioserica.
  • Delivery of audited financial statements by Bioserica by May 31, 2025.
  • No material adverse effect on either party.
  • Completion of shareholder redemptions by ASPAC III.

Outlook, Risks, and Contingencies

Outlook: The Company intends to file a registration statement containing a proxy statement/prospectus for shareholder voting. The transaction is not yet definitive and remains subject to negotiation of final terms.
Termination Rights: The Purchaser Parties may terminate the agreement if audited financial statements are not delivered by May 31, 2025. Either party may terminate by mutual agreement.
Risks:

  • Failure to obtain shareholder approval.
  • Regulatory hurdles, specifically CSRC filing requirements.
  • High level of shareholder redemptions reducing trust account funds.
  • Forward-looking statements regarding future performance are not guarantees.

Investor Verification Checklist

  • Definitive Agreements: Confirm execution of final merger documents beyond this initial agreement.
  • Financial Statements: Verify the delivery of Bioserica's audited financial statements by the May 31, 2025 deadline.
  • Regulatory Approvals: Monitor the status of the CSRC filing and SEC registration statement effectiveness.
  • Shareholder Voting: Review the upcoming Proxy Statement/Prospectus for voting instructions and redemption rights.
  • Redemption Levels: Assess the potential impact of shareholder redemptions on the transaction's liquidity and completion.